Salmafatima S Abadin1, Nancy L Zoellner1, Melody Schaeffer1, Bree Porcelli2, David H Gutmann3, Kimberly J Johnson4. 1. Brown School, Washington University, St. Louis, MO. 2. School of Medicine, Washington University, St. Louis, MO. 3. Department of Neurology, School of Medicine, Washington University, St. Louis, MO. 4. Brown School, Washington University, St. Louis, MO; Department of Pediatrics, School of Medicine, Washington University, St. Louis, MO. Electronic address: kijohnson@wustl.edu.
Abstract
OBJECTIVE: To evaluate evidence for differences in pediatric brain tumor diagnoses by race and ethnicity using a cross-sectional study design in individuals with neurofibromatosis type 1 (NF1). STUDY DESIGN: Subjects with NF1 were ascertained from the NF1 Patient Registry Initiative and through a clinical record database of patients at a large academic medical center. Logistic regression was employed to calculate ORs and 95% CIs to analyze differences in the odds of brain tumor diagnosis by race (White, Black, Asian, other/unknown) and ethnic (Hispanic vs non-Hispanic) groups. RESULTS: Data from a total of 1546, 629, and 2038 individuals who were ascertained from the NF1 Patient Registry Initiative, clinical records, and pooled datasets were analyzed, respectively. After adjusting for birth year, we observed a significantly reduced odds of brain tumor diagnoses in individuals self-identified or clinically reported as Black (OR = 0.13, 95% CI 0.05-0.31), Asian (OR = 0.15, 95% CI 0.04-0.64), and other/unknown (OR = 0.61, 95% CI 0.41-0.93) race compared with those with reported as White race. There was no significant difference in the odds of pediatric brain tumor diagnosis by Hispanic ethnicity. CONCLUSIONS: Consistent with prior smaller studies, these data suggest that pediatric brain tumor diagnoses vary by race in individuals with NF1. Reasons underlying observed differences by race warrant further investigation.
OBJECTIVE: To evaluate evidence for differences in pediatric brain tumor diagnoses by race and ethnicity using a cross-sectional study design in individuals with neurofibromatosis type 1 (NF1). STUDY DESIGN: Subjects with NF1 were ascertained from the NF1Patient Registry Initiative and through a clinical record database of patients at a large academic medical center. Logistic regression was employed to calculate ORs and 95% CIs to analyze differences in the odds of brain tumor diagnosis by race (White, Black, Asian, other/unknown) and ethnic (Hispanic vs non-Hispanic) groups. RESULTS: Data from a total of 1546, 629, and 2038 individuals who were ascertained from the NF1Patient Registry Initiative, clinical records, and pooled datasets were analyzed, respectively. After adjusting for birth year, we observed a significantly reduced odds of brain tumor diagnoses in individuals self-identified or clinically reported as Black (OR = 0.13, 95% CI 0.05-0.31), Asian (OR = 0.15, 95% CI 0.04-0.64), and other/unknown (OR = 0.61, 95% CI 0.41-0.93) race compared with those with reported as White race. There was no significant difference in the odds of pediatric brain tumor diagnosis by Hispanic ethnicity. CONCLUSIONS: Consistent with prior smaller studies, these data suggest that pediatric brain tumor diagnoses vary by race in individuals with NF1. Reasons underlying observed differences by race warrant further investigation.
Authors: Elina Uusitalo; Jussi Leppävirta; Anna Koffert; Sakari Suominen; Jussi Vahtera; Tero Vahlberg; Minna Pöyhönen; Juha Peltonen; Sirkku Peltonen Journal: J Invest Dermatol Date: 2014-10-29 Impact factor: 8.551
Authors: Ellen Plasschaert; Mie-Jef Descheemaeker; Lien Van Eylen; Ilse Noens; Jean Steyaert; Eric Legius Journal: Am J Med Genet B Neuropsychiatr Genet Date: 2014-11-12 Impact factor: 3.568
Authors: Evelyn K Sharkey; Nancy L Zoellner; Salmafatima Abadin; David H Gutmann; Kimberly J Johnson Journal: Contemp Clin Trials Date: 2014-12-19 Impact factor: 2.226
Authors: Shruti Garg; Ellen Plasschaert; Mie-Jef Descheemaeker; Susan Huson; Martine Borghgraef; Annick Vogels; D Gareth Evans; Eric Legius; Jonathan Green Journal: J Autism Dev Disord Date: 2015-06
Authors: D H Gutmann; S A Rasmussen; P Wolkenstein; M M MacCollin; A Guha; P D Inskip; K N North; M Poyhonen; P H Birch; J M Friedman Journal: Neurology Date: 2002-09-10 Impact factor: 9.910
Authors: Kimberly J Johnson; Jennifer Cullen; Jill S Barnholtz-Sloan; Quinn T Ostrom; Chelsea E Langer; Michelle C Turner; Roberta McKean-Cowdin; James L Fisher; Philip J Lupo; Sonia Partap; Judith A Schwartzbaum; Michael E Scheurer Journal: Cancer Epidemiol Biomarkers Prev Date: 2014-09-05 Impact factor: 4.254
Authors: J M Friedman; Jack Arbiser; Jonathan A Epstein; David H Gutmann; Stephen J Huot; Angela E Lin; Bruce McManus; Bruce R Korf Journal: Genet Med Date: 2002 May-Jun Impact factor: 8.822
Authors: Chenan Zhang; Quinn T Ostrom; Helen M Hansen; Julio Gonzalez-Maya; Donglei Hu; Elad Ziv; Libby Morimoto; Adam J de Smith; Ivo S Muskens; Cassie N Kline; Zalman Vaksman; Hakon Hakonarson; Sharon J Diskin; Carol Kruchko; Jill S Barnholtz-Sloan; Vijay Ramaswamy; Francis Ali-Osman; Melissa L Bondy; Michael D Taylor; Catherine Metayer; Joseph L Wiemels; Kyle M Walsh Journal: Neuro Oncol Date: 2020-11-26 Impact factor: 12.300
Authors: Ivo S Muskens; Chenan Zhang; Adam J de Smith; Jaclyn A Biegel; Kyle M Walsh; Joseph L Wiemels Journal: Neuro Oncol Date: 2019-11-04 Impact factor: 12.300
Authors: Laura J Smithson; Corina Anastasaki; Ran Chen; Joseph A Toonen; Sidney B Williams; David H Gutmann Journal: Semin Cell Dev Biol Date: 2016-06-03 Impact factor: 7.727
Authors: George S Stoyanov; Deyan Dzhenkov; Peter Ghenev; Bogomil Iliev; Yavor Enchev; Anton B Tonchev Journal: Med Oncol Date: 2018-01-31 Impact factor: 3.064
Authors: Bree Porcelli; Nancy L Zoellner; Salmafatima S Abadin; David H Gutmann; Kimberly J Johnson Journal: Fam Cancer Date: 2016-04 Impact factor: 2.375